| Drug Name |
Neostigmine |
| Drug ID |
BADD_D01553 |
| Description |
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. |
| Indications and Usage |
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone. |
| Marketing Status |
approved; vet_approved |
| ATC Code |
N07AA01; S01EB06 |
| DrugBank ID |
DB01400
|
| KEGG ID |
D08261
|
| MeSH ID |
D009388
|
| PubChem ID |
4456
|
| TTD Drug ID |
D08USJ
|
| NDC Product Code |
71872-7178; 43598-528; 43598-529 |
| UNII |
3982TWQ96G
|
| Synonyms |
Neostigmine | Synstigmin | Proserine | Prozerin | Polstigmine | Neostigmine Bromide | Bromide, Neostigmine | Syntostigmine | Neostigmine Methylsulfate | Methylsulfate, Neostigmine | Prostigmine | Prostigmin |
